Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The Investment Committee give you their top stocks to watch for the second half.
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
This was the stock's fourth consecutive day of gains.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Gemini 2.0 Flash is the base model that powers the free version of Gemini. It replaces Gemini 1.5 Flash which was released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback